| 注册
首页|期刊导航|中国临床药理学杂志|瑞舒伐他汀联合阿托伐他汀治疗急性脑梗死合并高脂血症患者的临床研究

瑞舒伐他汀联合阿托伐他汀治疗急性脑梗死合并高脂血症患者的临床研究

凡奇 马龙

中国临床药理学杂志2024,Vol.40Issue(18):2611-2615,5.
中国临床药理学杂志2024,Vol.40Issue(18):2611-2615,5.DOI:10.13699/j.cnki.1001-6821.2024.18.001

瑞舒伐他汀联合阿托伐他汀治疗急性脑梗死合并高脂血症患者的临床研究

Clinical trial of rosuvastatin combined with atorvastatin in the treatment of patients with acute ischemic stroke and hyperlipidemia

凡奇 1马龙1

作者信息

  • 1. 亳州市人民医院神经内科,安徽亳州 236800
  • 折叠

摘要

Abstract

Objective To explore the influence of rosuvastatin combined with atorvastatin on lipid metabolism,cerebral hemodynamics and neurological function in patients with acute ischemic stroke(AIS)complicated with hyperlipidemia.Methods Patients in the treatment group were oral administered with rosuvastatin calcium tablets 20 mg at bedtime on the basis of basic treatment,qd;patients in the control group were oral administered with atorvastatin tablets 60 mg before going to bed on the basis of basic treatment,qd,for 10 d.The clinical efficacy of the two groups was compared.The changes and safety of neurological function indexes[National Institutes of Health Stroke Scale(NIHSS),modified Rankin Scale(mRS)],lipid metabolism indexes[total cholesterol(TC),low density lipoprotein(LDL),high density lipoprotein(HDL)],cerebral hemodynamics indexes[peak systolic velocity(Vs),mean velocity(Vm)and pulsatility index(PI)of middle cerebral artery]and carotid plaque related indexes[intima-media thickness(IMT)and proportion of low echo plaque]before and after treatment were observed.And the safety evaluation is carried out.Results Finally,47 cases and 45 cases were included in the treatment group and the control group,respectively.After treatment,the total effective rate of the treatment group and the control group was 95.74%and 86.67%,respectively,with no statistical significance(P>0.05).After treatment,the NIHSS scores of treatment group and control group were(5.59±1.03)and(7.21±1.38)points,respectively;mRS scores were(1.95±0.24)and(2.38±0.26)points,respectively;TC levels were(2.79±0.41)and(3.28±0.45)mmol·L-1,respectively;LDL levels were(2.57±0.43)and(2.92±0.40)mmol·L-1,respectively;Vs levels were(80.67±3.71)and(76.28±5.13)cm·s-1;Vm levels were(47.52±4.16)and(44.07±4.86)cm·s-1,respectively;PI were 0.85±0.13 and 1.04±0.19;IMT were(1.58±0.21)and(1.76±0.19)mm,respectively;the proportion of hypoechoic plaque were 17.02%and 35.56%,respectively.There were statistically significant differences between the above indexes in the treatment group and the control group(all P<0.05).The adverse drug reactions in treatment group mainly included gastrointestinal reaction,headache and dizziness,muscle pain.The adverse drug reactions in control group mainly included gastrointestinal reaction,headache and dizziness,fatigue.The total incidence rates of adverse drug reactions in treatment group and control group were 6.38%and 8.89%,respectively(P>0.05).Conclusion Rosuvastatin and atorvastatin have a good therapeutic effect on AIS with hyperlipidemia.However,rosuvastatin has a better effect on improving lipid metabolism and cerebral hemodynamics,and promote the recovery of neurological function.

关键词

瑞舒伐他汀钙片/阿托伐他汀片/急性脑梗死/高脂血症/脂代谢/脑血流动力学/神经功能

Key words

rosuvastatin calcium tablet/atorvastatin tablet/acute cerebral infarction/hyperlipidemia/lipid metabolism/cerebral hemodynamics/neurological function

分类

医药卫生

引用本文复制引用

凡奇,马龙..瑞舒伐他汀联合阿托伐他汀治疗急性脑梗死合并高脂血症患者的临床研究[J].中国临床药理学杂志,2024,40(18):2611-2615,5.

中国临床药理学杂志

OA北大核心CSTPCD

1001-6821

访问量0
|
下载量0
段落导航相关论文